The global coronary artery bypass graft market is projected to reach USD 18,700.6 million by 2025 and continue its upward trajectory with a CAGR of 2.9%, reaching approximately USD 24,887.3 million by ...

Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira," "Inspira Technologies" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that its U.

Patients with chronic kidney disease (CKD) often encounter cardiovascular complications, most commonly coronary heart disease. Although coronary artery bypass grafting is an effective treatment for ...

Age, diuretic use, cardiopulmonary bypass time (CPBT), and valve surgery were independent predictors of PPM requirement. After 5.6 ± 4.2 years of follow-up, 40% of the patients were PPM dependent.

undergoing cardiac surgery with cardiopulmonary bypass (CPB) 2. At Alexion, AstraZeneca Rare Disease, we are committed to continuing to investigate the potential role of the complement system in ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Patients with chronic kidney disease (CKD) often encounter cardiovascular complications, most commonly ...

PESG Research releases an update following groundbreaking clinical evaluation results: Inspira Technologies* (NASDAQ: IINN) has reported exceptional clinical study outcomes for its HYLA blood sensor, ...